NCT05447663View on ClinicalTrials.gov

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
Acute Myeloid LeukemiaAllogeneic Stem Cell Transplantation
Interventions
DRUG

Siremadlin

Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).

Trial Locations (6)

24127

Novartis Investigative Site, Bergamo

40138

Novartis Investigative Site, Bologna

41013

Novartis Investigative Site, Seville

46026

Novartis Investigative Site, Valencia

79106

Novartis Investigative Site, Freiburg im Breisgau

86179

Novartis Investigative Site, Augsburg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY